

Orthocell receives new US patent for CelGro®

- **New US divisional patent granted for CelGro®**
- Patent covers the **method of manufacture of collagen medical devices and as an aid in the surgical repair of soft tissue injuries**
- CelGro® patents have been previously **granted in the US, Canada, Europe, China, Japan, Singapore, Australia and New Zealand**
- **CelGro® dental (recently renamed Striate+) approved for use in US, Europe and Australia**
- Global addressable market for CelGro® is in excess of >US\$10bn¹ and growing.

Perth, Australia; 15 February 2021: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has been granted a new US divisional patent for CelGro®. The patents entitled “**Method for Producing a Collagen Membrane and Uses Thereof**” provides additional important intellectual property (IP) to protect the CelGro® platform for soft tissue regeneration and repair applications expiring in June 2033.

Orthocell Managing Director Paul Anderson, said: “This is an important patent that further protects and strengthens our IP position for CelGro® providing greater layers of protection. This patent also complements the recent market approval of the first CelGro® product, Striate+ for dental bone and soft tissue repair procedures approved in the US, EU and Australia.”

Orthocell has secured 11 patent families covering its portfolio of breakthrough regenerative medicine products, comprising 110 separate patents/applications, of which 75 are granted. CelGro® is a customisable collagen medical device manufactured by the Company at its quality controlled (GMP) facility in WA, using the Company’s proprietary SMRT™ tissue engineering process. The Company believes CelGro® has numerous competitive advantages over existing synthetic and biologic tissue repair devices, particularly in the areas of cell biocompatibility, tensile strength and the promotion of high-quality tissue repair. Use of CelGro® has shown to result in high quality outcomes in the repair of bone defects in the jaw, assist in the re-joining of severed or damaged peripheral nerves and augment repair of the rotator cuff tendon within the shoulder.

Striate+ is the first product from the CelGro® platform technology to gain US, EU and AUS approval. Based on surgeon feedback, it has distinct advantages over other similar products and may assist surgeons to deliver improved patient outcomes through superior handling characteristics, tissue integration qualities and improved bone healing. With major market approvals achieved and key opinion leaders actively engaging with the program, Orthocell is well positioned to secure a distribution partner and establish Striate+ as the best-in-class dental resorbable collagen membrane.

Release authorised by Paul Anderson
Managing Director

¹ US, Japanese, European and Australian markets



For personal use only

Orthocell Ltd.

For more information, please contact:

General & Investor enquiries

Paul Anderson

Orthocell Limited

Managing Director

P: +61 8 9360 2888

E: paul.anderson@orthocell.com.au

Media enquiries

Haley Chartres

HACK Director

P: +61 423 139 163

E: haley@hck.digital

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell's portfolio of products include CelGro[®], a collagen medical device which facilitates tissue repair and healing in a variety of dental, nerve and orthopaedic, reconstructive applications. Orthocell recently received FDA 510(k) approval for Striate+, the first application of the CelGro[®] platform for dental GBR applications. Striate+ is also approved in Australia (ARTG) and Europe (CE Mark) for the same. The Company's other major products are the cell therapies Autologous Tenocyte Implantation (Ortho-ATI[®]) and Autologous Chondrocyte Implantation (Ortho-ACI[®]), which aim to regenerate damaged tendon and cartilage tissue respectively. Orthocell is moving forward with Ortho-ATI[®] clinical studies designed to assist in the US (FDA) approval process and has completed its pre-IND meetings with the FDA.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter [@OrthocellLtd](https://twitter.com/OrthocellLtd) and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.



For personal use only